Quizartinib

Chemical formula: C₂₉H₃₂N₆O₄S Molecular mass: 560.221 g/mol PubChem compound: 24889392

Therapeutic indications

Quizartinib is indicated for:

Acute myeloid leukaemia that is FLT3-ITD positive

Population group: only adults (18 years old or older)

Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

35.4 mg once daily for 2 weeks in each induction and consolidation cycle, followed by maintenance therapy starting dose of 26.5 mg once daily for 2 weeks and thereafter 53 mg once daily for 2 weeks

Contraindications

Quizartinib is contraindicated in the following cases:

Pregnancy

Lactation

Congenital long QT syndrome

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.